Fosbretabulin disodium (Synonyms: 康普瑞汀磷酸二钠; CA 4DP; CA 4P; Combretastatin A4 disodium phosphate)

目录号: HY-17449 纯度: 99.47%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Fosbretabulin disodium (CA 4DP) 是微管蛋白去稳定剂。Fosbretabulin disodium 是 Combretastatin A4 前体，可选择性靶向内皮细胞，诱导新生肿瘤新血管消退，减少肿瘤血流量并引起中央肿瘤坏死。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Fosbretabulin disodium Chemical Structure

CAS No. : 168555-66-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥353	In-stock
5 mg	￥687	In-stock
10 mg	￥1100	In-stock
25 mg	￥2000	In-stock
50 mg	￥3000	In-stock
100 mg	￥4500	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of Fosbretabulin disodium:

Fosbretabulin 询价
Fosbretabulin tromethamine 询价

Fosbretabulin disodium 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis^[1]^[3].

IC₅₀ & Target

tubulin^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	GI₅₀	0.32 μM Compound: CA-4P; 3	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 30580241]
A-375	IC₅₀	0.0016 μM Compound: CA4P	Growth inhibition of human A375 cells measured after 48 hrs by MTS assay Growth inhibition of human A375 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
A549	IC₅₀	0.0234 μM Compound: CA4P	Growth inhibition of human A549 cells by MTS assay Growth inhibition of human A549 cells by MTS assay	[PMID: 27100701]
A549	GI₅₀	0.16 μM Compound: CA-4P; 3	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30580241]
A549	IC₅₀	0.4 μM Compound: CA-4P	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
Bel-7402	IC₅₀	0.04 μM Compound: CA-4p	Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by SRB assay Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by SRB assay	[PMID: 32113125]
BXPC-3	GI₅₀	0.23 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 22324723]
BXPC-3	GI₅₀	0.23 μg/mL Compound: CA4P	Antitumor activity against human BxPC3 cells by sulforhodamine B assay Antitumor activity against human BxPC3 cells by sulforhodamine B assay	[PMID: 19228038]
Caov-3 cell line	IC₅₀	13.11 nM Compound: CA4P	Antiproliferative activity against human Caov3 cells measured after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human Caov3 cells measured after 96 hrs by Celltiter-Glo assay	[PMID: 27718473]
CCRF-CEM	IC₅₀	0.011 μM Compound: 7; CA-4P	Antiproliferative activity against human CEM cells measured after 96 hrs by Coulter counter method Antiproliferative activity against human CEM cells measured after 96 hrs by Coulter counter method	[PMID: 30921759]
CCRF-CEM	IC₅₀	0.011 μM Compound: 4; CA-4P	Antiproliferative activity against human CEM cells after 96 hrs by coulter counting method Antiproliferative activity against human CEM cells after 96 hrs by coulter counting method	[PMID: 29471122]
CCRF-CEM	IC₅₀	95 nM Compound: CA-4P, combretastatin A4P	Antiproliferative activity against human CEM cells after 96 hrs by Coulter counter method Antiproliferative activity against human CEM cells after 96 hrs by Coulter counter method	[PMID: 25626146]
DU-145	GI₅₀	0.0007 μg/mL Compound: CA4P	Antitumor activity against human DU145 cells by sulforhodamine B assay Antitumor activity against human DU145 cells by sulforhodamine B assay	[PMID: 19228038]
DU-145	IC₅₀	0.0014 μM Compound: CA4P	Growth inhibition of human DU145 cells measured after 48 hrs by MTS assay Growth inhibition of human DU145 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
DU-145	GI₅₀	0.00323 μM Compound: CA-4P	Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
DU-145	GI₅₀	0.00323 μM Compound: CA4P	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 24183586]
DU-145	GI₅₀	0.0072 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 22324723]
DU-145	GI₅₀	0.016 μM Compound: 3, CA4P	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24016002]
HCT-116	IC₅₀	0.0016 μM Compound: CA4P	Growth inhibition of human HCT116 cells measured after 48 hrs by MTS assay Growth inhibition of human HCT116 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
HCT-116	IC₅₀	0.24 μM Compound: CA-4P	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
HeLa	IC₅₀	0.00043 μM Compound: 2, CA4-P	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19879758]
HeLa	IC₅₀	0.013 μM Compound: 7; CA-4P	Antiproliferative activity against human HeLa cells measured after 3 days by Coulter counter method Antiproliferative activity against human HeLa cells measured after 3 days by Coulter counter method	[PMID: 30921759]
HeLa	IC₅₀	0.013 μM Compound: 4; CA-4P	Antiproliferative activity against human HeLa cells after 3 days by coulter counting method Antiproliferative activity against human HeLa cells after 3 days by coulter counting method	[PMID: 29471122]
HeLa	GI₅₀	0.019 μM Compound: CA-4P; 3	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30580241]
HeLa	IC₅₀	0.56 μM Compound: CA-4P	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
HeLa	IC₅₀	79 nM Compound: CA-4P, combretastatin A4P	Antiproliferative activity against human HeLa cells after 4 days by Coulter counter method Antiproliferative activity against human HeLa cells after 4 days by Coulter counter method	[PMID: 25626146]
HepG2	IC₅₀	0.002 μM Compound: CA-4p	Antiproliferative activity against human HepG2 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by SRB assay	[PMID: 32113125]
HepG2	GI₅₀	0.19 μM Compound: CA-4P; 3	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30580241]
HepG2	IC₅₀	0.27 μM Compound: CA-4P	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
HMEC-1	IC₅₀	0.0029 μM Compound: 7; CA-4P	Antiproliferative activity against human HMEC1 cells measured after 4 days by Coulter counter method Antiproliferative activity against human HMEC1 cells measured after 4 days by Coulter counter method	[PMID: 30921759]
HMEC-1	IC₅₀	0.0029 μM Compound: 4; CA-4P	Antiproliferative activity against human HMEC1 cells after 4 days by coulter counting method Antiproliferative activity against human HMEC1 cells after 4 days by coulter counting method	[PMID: 29471122]
HMEC-1	IC₅₀	2.9 nM Compound: CA-4P, combretastatin A4P	Antiproliferative activity against human HMEC1 cells after 4 days by Coulter counter method Antiproliferative activity against human HMEC1 cells after 4 days by Coulter counter method	[PMID: 25626146]
HT-29	GI₅₀	0.062 μM Compound: CA-4P; 3	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30580241]
HUVEC	GI₅₀	8 nM Compound: CA4P	Growth inhibition of HUVEC after 72 hrs by crystal violet staining-based assay Growth inhibition of HUVEC after 72 hrs by crystal violet staining-based assay	[PMID: 27690431]
Jurkat	EC₅₀	15 nM Compound: CA4P, Zybrestat	Cytotoxicity against human Jurkat cells assessed as cell viability after 48 hrs by trypan blue exclusion assay Cytotoxicity against human Jurkat cells assessed as cell viability after 48 hrs by trypan blue exclusion assay	[PMID: 24387982]
K562	IC₅₀	0.72 μM Compound: 7	Cytotoxicity against human K562 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 28143677]
KM-20L2	GI₅₀	0.034 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 22324723]
KM-20L2	GI₅₀	0.034 μg/mL Compound: 1b, CA4P	Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 16252907]
L1210	IC₅₀	0.0021 μM Compound: 4; CA-4P	Antiproliferative activity against mouse L1210 cells after 96 hrs by coulter counting method Antiproliferative activity against mouse L1210 cells after 96 hrs by coulter counting method	[PMID: 29471122]
L1210	IC₅₀	0.013 μM Compound: 7; CA-4P	Antiproliferative activity against mouse L1210 cells measured after 96 hrs by Coulter counter method Antiproliferative activity against mouse L1210 cells measured after 96 hrs by Coulter counter method	[PMID: 30921759]
L1210	IC₅₀	82 nM Compound: CA-4P, combretastatin A4P	Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method	[PMID: 25626146]
MCF7	IC₅₀	0.002 μM Compound: 2, CA4-P	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19879758]
MCF7	IC₅₀	0.011 μM Compound: CA-4p	Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay	[PMID: 32113125]
MCF7	IC₅₀	0.96 μM Compound: CA-4P	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
MDA-MB-231	IC₅₀	0.0028 μM Compound: CA4P	Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by MTS assay Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
MDA-MB-231	GI₅₀	0.065 μM Compound: CA-4P; 3	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30580241]
MDA-MB-231	IC₅₀	173.3 nM Compound: CA4P	Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs by Celltiter-Glo assay	[PMID: 27718473]
MDA-MB-435	IC₅₀	8.75 nM Compound: CA4P	Antiproliferative activity against human MDA-MB-435 cells measured after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-435 cells measured after 96 hrs by Celltiter-Glo assay	[PMID: 27718473]
MGC-803	IC₅₀	0.47 μM Compound: CA-4P	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 30108925]
NCI-H460	GI₅₀	0.0004 μg/mL Compound: CA4P	Antitumor activity against human NCI-H460 cells by sulforhodamine B assay Antitumor activity against human NCI-H460 cells by sulforhodamine B assay	[PMID: 19228038]
NCI-H460	GI₅₀	0.00194 μM Compound: CA-4P	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
NCI-H460	GI₅₀	0.00194 μM Compound: CA4P	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24183586]
NCI-H460	GI₅₀	0.029 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 22324723]
NCI-H460	GI₅₀	0.029 μg/mL Compound: 1b, CA4P	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 16252907]
NCI-H460	GI₅₀	0.066 μM Compound: 3, CA4P	Cytotoxicity against human NCI-H460 cells by SRB assay Cytotoxicity against human NCI-H460 cells by SRB assay	[PMID: 24016002]
P388	ED₅₀	0.0004 μg/mL Compound: 1b, CA4P	Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay	[PMID: 16252907]
P388	ED₅₀	0.0004 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis	[PMID: 22324723]
PBMC	IC₅₀	0.17 μM Compound: CA4P	Growth inhibition of human PBMC cells measured after 48 hrs by MTS assay Growth inhibition of human PBMC cells measured after 48 hrs by MTS assay	[PMID: 27100701]
PC-3	IC₅₀	0.0062 μM Compound: CA4P	Growth inhibition of human PC3 cells measured after 48 hrs by MTS assay Growth inhibition of human PC3 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
SF-268	GI₅₀	0.036 μg/mL Compound: 1b, CA4P, Fosbretabulin	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 22324723]
SF-268	GI₅₀	0.036 μg/mL Compound: 1b, CA4P	Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 16252907]
SK-OV-3	GI₅₀	0.00119 μM Compound: CA-4P	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
SK-OV-3	GI₅₀	0.00119 μM Compound: CA4P	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 24183586]
SK-OV-3	IC₅₀	0.0077 μM Compound: CA4P	Growth inhibition of human SKOV3 cells measured after 48 hrs by MTS assay Growth inhibition of human SKOV3 cells measured after 48 hrs by MTS assay	[PMID: 27100701]
TOV112D	IC₅₀	30.85 nM Compound: CA4P	Antiproliferative activity against human TOV112D cells measured after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human TOV112D cells measured after 96 hrs by Celltiter-Glo assay	[PMID: 27718473]

体外研究
(In Vitro)

FosbretabuLin disodium 抑制白血病 P-388、胰腺 BXPC-3、成神经细胞 SK-N-SH、甲状腺 SW1736、肺-NSC NCI-H460、前列腺 DU-145、咽 FADU 的生长，EC₅₀ 分别为 0.0029、0.23、0.00025、0.00061、0.00035、0.00072 和 0.00045 μg/mL^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

FosbretabuLin disodium (100 mg/kg；ip) 在给药后 1 小时和 6 小时增加平均动脉血压 (MABP)，并降低大鼠的肿瘤血流量^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumor^[3]
Dosage:	100 mg/kg
Administration:	A single i.p. injections
Result:	Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration. Reduced the blood flow in the tumor.

Clinical Trial

分子量

440.29

Formula

C₁₈H₁₉Na₂O₈P

CAS 号

168555-66-6

性状

固体

颜色

White to off-white

中文名称

康普瑞汀磷酸二钠

结构分类

Stilbenes

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

细胞实验：

H₂O 中的溶解度 : 4.5 mg/mL (10.22 mM; 超声加热助溶)

DMF 中的溶解度 : < 1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2712 mL	11.3562 mL	22.7123 mL
5 mM	0.4542 mL	2.2712 mL	4.5425 mL
10 mM	0.2271 mL	1.1356 mL	2.2712 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 14.29 mg/mL (32.46 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.47%

选择批次：

Data Sheet (626 KB) SDS (393 KB)

COA (188 KB) HNMR (165 KB) LCMS (394 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160(8):2008-27. [Content Brief]

[2]. Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 2005 Jun 16;48(12):4087-99. [Content Brief]

[3]. Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626-34. [Content Brief]

Fosbretabulin disodium 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	2.2712 mL	11.3562 mL	22.7123 mL	56.7808 mL
	5 mM	0.4542 mL	2.2712 mL	4.5425 mL	11.3562 mL
	10 mM	0.2271 mL	1.1356 mL	2.2712 mL	5.6781 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fosbretabulin disodium168555-66-6CA 4DP CA 4PCombretastatin A4 disodium康普瑞汀磷酸二钠Microtubule/TubulinApoptosistubulindestabilizingendothelianascenttumourneovesselsInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Fosbretabulin disodium (Synonyms: 康普瑞汀磷酸二钠; CA 4DP; CA 4P; Combretastatin A4 disodium phosphate)

Other Forms of Fosbretabulin disodium:

Fosbretabulin disodium 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Fosbretabulin disodium 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Fosbretabulin disodium (Synonyms: 康普瑞汀磷酸二钠; CA 4DP; CA 4P; Combretastatin A4 disodium phosphate)

Other Forms of Fosbretabulin disodium:

Fosbretabulin disodium 相关抗体

Fosbretabulin disodium 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Fosbretabulin disodium 相关抗体:

摩尔计算器

稀释计算器

Fosbretabulin disodium 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z